PR 000001

Drug Profile

PR 000001

Latest Information Update: 05 Oct 1998

Price : $50

At a glance

  • Originator POLA
  • Class Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Dopamine uptake inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Parkinson's disease

Most Recent Events

  • 05 Oct 1998 No-Development-Reported for Parkinson's disease in Japan (Unknown route)
  • 30 Jan 1996 Preclinical development for Parkinson's disease in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top